00954 常茂生物
按盘价 
0.355 +0.005 (+1.429%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 资产回报率 (%) | -5.496% | -5.476% | -7.027% | 7.528% | 6.466% |
| 股东资金回报率 (%) | -12.137% | -11.050% | -12.034% | 11.036% | 8.662% |
| 资本运用回报率 (%) | -10.560% | -10.577% | -9.382% | 8.729% | 8.333% |
边际利润分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | 3.202% | 2.869% | 4.051% | 24.770% | 7.059% |
| 未计利息、税项、折旧及摊销前利润率 (%) | 0.820% | -1.958% | -1.460% | 16.653% | 20.993% |
| 税前边际利润率 (%) | -11.665% | -11.557% | -9.195% | 12.005% | 15.404% |
| 纯利率 (%) | -11.988% | -11.670% | -13.508% | 11.153% | 10.642% |
变现能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流动比率 (X) | 0.495 X | 0.494 X | 1.040 X | 1.321 X | 1.235 X |
| 速动比率 (X) | 0.294 X | 0.257 X | 0.634 X | 0.734 X | 0.756 X |
财务杠杆分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 总负债 / 总资产比率 (%) | 56.247% | 53.324% | 47.558% | 35.456% | 27.076% |
| 总债项 / 总资产比率 (%) | 45.695% | 42.899% | 39.811% | 24.156% | 9.331% |
| 净债项 / 总资产比率 (%) | 39.918% | 38.261% | 32.603% | 19.184% | 3.202% |
| 总债项 / 股东资金比率 (%) | 104.333% | 91.891% | 75.902% | 37.443% | 12.804% |
| 长期债项 / 股东资金比率 (%) | 11.718% | 3.551% | 38.589% | 19.688% | 0.254% |
| 净债项 / 股东资金比率 (%) | 91.143% | 81.956% | 62.160% | 29.737% | 4.393% |
| 净现金 / (债项) ($) | (4.71亿) | (4.78亿) | (4.05亿) | (2.32亿) | (3.06千万) |
| 每股净现金 / (债项) ($) | (0.889) | (0.903) | (0.765) | (0.437) | (0.058) |
| 总债项 / 资本运用比率 (%) | 85.265% | 83.095% | 53.926% | 31.252% | 12.754% |
| 利息盈利率 (X) | N/A | N/A | N/A | 33.838 X | 44.242 X |
营运效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存货周转率日数 (日) | 85.889日 | 88.493日 | 87.474日 | 94.311日 | 89.027日 |
| 应收贸易帐周转率日数 (日) | 45.382日 | 47.104日 | 46.796日 | 40.813日 | 52.411日 |
| 应付贸易帐周转率日数 (日) | 17.921日 | 18.559日 | 27.876日 | 40.584日 | 58.120日 |
| 备注： | 实时报价更新时间为01/04/2026 11:55 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB -66,763 |
| 增长率 | -2.169% |
| 每股盈利/(亏损) | RMB -0.126 |
| 每股账面资产净值 (¥) | RMB 0.975 |